share_log

藥明康德：截至2024年6 月30日止六個月未經審計中期業績公告

WUXI APPTEC: ANNOUNCEMENT OF THE UNAUDITED INTERIM RESULTSFOR THE SIX MONTHS ENDED JUNE 30, 2024

HKEX ·  Jul 29, 2024 12:11

Summary by Moomoo AI

药明康德公布截至2024年6月30日止六個月未經審計中期業績，收入達人民幣17,240.9百萬元，同比下降8.6%；毛利為人民幣6,700.9百萬元，同比下降11.3%。母公司持有者之應佔溢利為人民幣4,239.8百萬元，同比減少20.2%。每股盈利基本為人民幣1.46元，攤薄為人民幣1.45元。公司為全球醫藥及生命科學行業提供一體化、端到端的新藥研發和生產服務，擁有超過6,000家活躍客戶基礎。公司在手訂單人民幣431.0億元，剔除新冠商業化項目同比增長33.2%。公司面臨外部環境的不確定性，預計2024年收入可達到人民幣383–405億元，剔除新冠商業化項目後將保持正增長。
药明康德公布截至2024年6月30日止六個月未經審計中期業績，收入達人民幣17,240.9百萬元，同比下降8.6%；毛利為人民幣6,700.9百萬元，同比下降11.3%。母公司持有者之應佔溢利為人民幣4,239.8百萬元，同比減少20.2%。每股盈利基本為人民幣1.46元，攤薄為人民幣1.45元。公司為全球醫藥及生命科學行業提供一體化、端到端的新藥研發和生產服務，擁有超過6,000家活躍客戶基礎。公司在手訂單人民幣431.0億元，剔除新冠商業化項目同比增長33.2%。公司面臨外部環境的不確定性，預計2024年收入可達到人民幣383–405億元，剔除新冠商業化項目後將保持正增長。
On June 30, 2024, WuXi AppTec announced its unaudited interim results for the six months ended that day. Revenue reached 1,724.09 million RMB, a 8.6% YoY decrease. Gross profit was 670.09 million RMB, a 11.3% YoY decrease. Net profit attributable to the company's shareholders was 423.98 million RMB, a 20.2% decrease YoY. Basic earnings per share were 1.46 RMB, diluted to 1.45 RMB. The company provides end-to-end new drug R&D and production services for the global pharmaceutical and life sciences industry, with more than 6,000 active customer base. The company holds orders worth 43.1 billion RMB, with a YoY growth of 33.2% excluding the commercialization of COVID-19 projects. The company faces uncertainty from the external environment, but is expected to maintain positive growth after excluding COVID-19 commercialization projects, with an estimated revenue of 38.3-40.5 billion RMB in 2024.
On June 30, 2024, WuXi AppTec announced its unaudited interim results for the six months ended that day. Revenue reached 1,724.09 million RMB, a 8.6% YoY decrease. Gross profit was 670.09 million RMB, a 11.3% YoY decrease. Net profit attributable to the company's shareholders was 423.98 million RMB, a 20.2% decrease YoY. Basic earnings per share were 1.46 RMB, diluted to 1.45 RMB. The company provides end-to-end new drug R&D and production services for the global pharmaceutical and life sciences industry, with more than 6,000 active customer base. The company holds orders worth 43.1 billion RMB, with a YoY growth of 33.2% excluding the commercialization of COVID-19 projects. The company faces uncertainty from the external environment, but is expected to maintain positive growth after excluding COVID-19 commercialization projects, with an estimated revenue of 38.3-40.5 billion RMB in 2024.
Helpful
Not Helpful

This announcement is a separate document:

Doc 1     View Translation

Disclaimer: This content is for informational and educational purposes only and does not constitute a recommendation or endorsement of any specific investment or investment strategy. Read more
Comment Comment · Views 250

Recommended

Related Stocks Related Stocks
Symbol Mini Chart Price
KING INTL INV
00928
0.030
BIOCYTOGEN-B
02315
9.190
MABPHARM-B
02181
0.330
TYK MEDICINES-B
02410
32.350
CT ENTERPRISE
03839
1.620
Log In for the Full List
Reassessing Chinese Assets
Following the introduction of China's groundbreaking DeepSeek technology, Wall Street giants have revised their investment outlooks for the Chinese market.
Discussing
Tesla's earnings caused fluctuations, what's your market outlook？
Tesla's Q4 2024 revenue was $25.71 billion, up 2% year-on-year but below expectations. Can Tesla's stock price keep rising in 2025 with Trum Show More
Tesla's Q4 results are out. Will you get on board?
64%
36%
Hold firm
Wait and see
6096 votes
TSLA earnings preview: Grab rewards by guessing the opening price!
Hi, mooers! Cheerlead
TSLA is releasing its Q4 2024 earnings on January 29 after the bell. Unlock insights with TSLA Earnings Hub>>
Don't want to miss first-hand information? Subscribe to @Moo Live and book the earnings conference live stream NOW!
For the details of indicator sentiment, please tap the link and check.
Since its Q3 2024 earnings release, shares of $Tesla (TSLA.US)$ have a increase of 99.47%. How will the market react to the...

Statement

This page is machine-translated. Moomoo tries to improve but does not guarantee the accuracy and reliability of the translation, and will not be liable for any loss or damage caused by any inaccuracy or omission of the translation.
OK